Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of wingbeat kinematics and muscle size on maximum flight speed in hummingbirds.

The Journal of experimental biology·2026
Same author

DYNO-MILL-Assisted Mechanochemistry: Design of Experiments Optimization for Sustainable Synthesis of Pyrrolo[3,4-c]pyrazoles.

ChemSusChem·2026
Same author

Computer vision analysis to identify episodic flapping in hovering hummingbirds.

Biology open·2026
Same author

Novel Triazoloquinoxaline-Based Tubulin Polymerization Inhibitor Induces Necroptosis and Significantly Inhibits Metastatic Melanoma Tumor Growth.

Journal of medicinal chemistry·2026
Same author

Catalyst-Free Electro-photochemical Hydroalkylation of <i>N</i>‑Aryl Maleimides via Alternate Electrode Electrolysis: A Sustainable Route to <i>N</i>‑Aryl Succinimides with Quaternary Center.

JACS Au·2026
Same author

Development of an Extended-release Formulation of Radioprotectin-1 for Mitigation of Gastrointestinal Acute Radiation Syndrome.

Radiation research·2026

Related Experiment Video

Updated: Jun 11, 2025

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.9K

Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study.

Prateek Rai1,2, Christopher J Clark1,2, Carl B Womack3

  • 1Molecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.

Molecules (Basel, Switzerland)
|September 28, 2024
PubMed
Summary

Drug resistance in cancer is a major challenge. A new compound, ATX-1d, targets the autotaxin (ATX) pathway, enhancing chemotherapy effectiveness against resistant cancer cells.

Keywords:
QM/MM-GBSASAPTautotaxinbreast cancercombination therapymelanomamolecular simulations

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.3K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

Related Experiment Videos

Last Updated: Jun 11, 2025

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

22.9K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.3K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Drug resistance significantly contributes to cancer mortality, with Taxol resistance affecting over 50% of ovarian and 30-40% of breast cancer patients.
  • Cancer therapies can induce resistance by activating the autotaxin (ATX)-lysophosphatidic acid (LPA)-lysophosphatidic acid receptor (LPAR) signaling axis, promoting cancer cell survival.
  • Targeting the ATX-LPA-LPAR axis is a promising strategy to overcome therapeutic resistance in various cancers.

Purpose of the Study:

  • To identify and evaluate a novel compound, ATX-1d, designed to inhibit the ATX signaling pathway.
  • To assess the potential of ATX-1d in combination therapy to overcome drug resistance in cancer cells.

Main Methods:

  • Computational methods (MM-GBSA, QM/MM-GBSA, SAPT) were used for in silico assessment of ATX-1d binding affinity.
  • In vitro assays were conducted to determine the inhibitory concentration (IC50) of ATX-1d against ATX.
  • The efficacy of ATX-1d in combination with paclitaxel was evaluated in 4T1 murine breast carcinoma and A375 human melanoma cell lines.

Main Results:

  • ATX-1d demonstrated potent inhibition of ATX with an IC50 of 1.8 ± 0.3 μM and significant binding affinity.
  • In vitro, ATX-1d significantly enhanced the efficacy of paclitaxel, increasing its potency by tenfold in 4T1 cells and fourfold in A375 cells.
  • ATX-1d did not exhibit cytotoxic effects when used as a single agent.

Conclusions:

  • The novel compound ATX-1d effectively targets the ATX pathway and shows promise in overcoming chemotherapy resistance.
  • Combining ATX-1d with paclitaxel represents a potential therapeutic strategy to improve treatment outcomes for resistant breast and melanoma cancers.
  • Further investigation into ATX-1d as a sensitizer for conventional chemotherapies is warranted.